ACROBiosystems, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business model innovation. Over the years, we have established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes.

Cell and gene therapy remains one of the major product lines. Cell therapy research has never been more exciting with new advances and insights. Breakthroughs such as CAR-NK and new CAR constructs are just around the corner towards commercialization, with newly discovered target antigens. However, it has also never been more challenging with ever-changing regulations and manufacturing guidelines.

With our products and reagents, all of us at ACROBiosystems strive to provide the highest quality products possible, tailored for your cell and gene therapy needs and applications.